A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia

Trial Profile

A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms CaLLypso
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
    • 26 Jan 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top